SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: EX-10.7
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/ex10-7.htm

Chunk 4 of 7
Word Count: 1465
Character Count: 9370

Document Content:

to be Sold, or the Licensed Method to be practiced, under this Agreement. Licensee shall pay the attorneys’ fees and other costs incurred if those efforts were incurred in the prosecution of the patents even if those efforts were incurred prior to the Effective Date but the bill therefor has not been included in the calculation of the amount to be paid pursuant to Section 4.2 above. 16. PATENT MARKING The Licensee will mark all Licensed Products and Licensed Methods made, used or Sold under the terms of this Agreement or their containers in accordance with the applicable patent marking laws. 17. PATENT INFRINGEMENT the event that HFHS or the Licensee learns of infringement of potential commercial significance of any Patent Rights, the knowledgeable party will provide the other (i) with written notice of such infringement and (ii) with any evidence of such infringement available to it (the “Infringement Notice”).

17.2 During
the term of this Agreement, the Licensee shall prosecute and/or defend, at its own expense and utilizing counsel of its choice, any infringement
of, and/or challenge to, the Patent Rights. Any recovery of damages shall be considered Earned Royalties for all purposes hereunder.
The Licensee shall indemnify and hold HFHS harmless against any costs, expenses or liability that may be found or assessed against HFHS
in any such suit. HFHS shall provide reasonable assistance to Licensee to enforce the Patent Rights with respect to any infringement,
including being a named party in a lawsuit to enforce the Patent Rights.

18. INDEMNIFICATION AND INSURANCE

18.1 The
Licensee will, and will require its Sublicensees to, indemnify, hold harmless and defend HFHS and its officers, employees and agents,
the sponsors of the research that led to Patent Rights and the inventors of the Patent Rights or any invention claimed in patents or
patent applications under Patent Rights (including Licensed Products and Licensed Methods contemplated thereunder) and their employers
against any and all claims, suits, losses, damage, costs, fees and expenses resulting from, or arising out of, the exercise of this license
or any sublicense. This indemnification will include, but not be limited to, any product liability. If HFHS, in its reasonable judgement,
believes that there will be a conflict of interest or it will not otherwise be adequately represented by counsel chosen by the Licensee
to defend HFHS in accordance with this Paragraph 18.1, then HFHS may retain counsel of its choice to represent it and the Licensee will
pay all expenses for such representation.

18.2 During
the term of this Agreement and for three (3) years following its termination or expiration, the Licensee, at its sole cost and expense,
shall obtain and maintain general liability insurance coverage in an amount no less than $250,000 to insure it against liability arising
from the Patent Rights and/or activities in connection with this License and to its indemnification obligations assumed under this Agreement;
evidence of which shall be provided to HFHS following execution of this agreement and subsequently on annual renewal of its policies
of insurance, and License shall provide prompt notice to HFHS of any cancellation in its coverage.

18.3 Upon
the earlier occurrence of (i) clinical validation of the Licensed Products and/or Licensed Methods or (ii) the use, licensing or sublicensing
of Licensed Products and Licensed Methods to diagnose or treat human beings, Licensee shall obtain and maintain appropriate coverage
of commercial general liability, and product liability insurance in the amount of no less than Three Million Dollars ($3,000,000) per
each occurrence/Five Million Dollars ($5,000,000) in the general aggregate to protect HFHS, its trustees, officers, employees, attorneys,
and agents under the indemnification provided hereunder. HFHS, its trustees, officers, employees, attorneys, and agents shall be named
as additional insureds on Licensee’s insurance policies and shall be provided appropriate certificates of insurance thereunder.

18.4 HFHS
will promptly notify the Licensee in writing of any claim or suit brought against HFHS for which HFHS intends to invoke the provisions
of this Article 18 (Indemnification and Insurance). The Licensee will keep HFHS informed of its defense of any claims pursuant to this
Article 18 (Indemnification and Insurance).

18.5 HFHS
may periodically evaluate the adequacy of the minimum coverage of insurance and deductible limits specified in this Section 18. HFHS
reserves the right to require Licensee to adjust the insurance coverage by modifying the types of required coverages, the limits and/or
financial rating and/or the method of financial rating of Licensee’s insurers as such changes are required of HFHS by its insurance
carrier. HFHS shall provide Licensee with reasonable notice, contingent on HFHS receiving timely notice from its insurance carrier, of
any proposed modification and, if so requested by Licensee, discuss any proposed modifications in good faith. Should any of the requirements
of this Section 18 not be available in the insurance market at commercially reasonable rates or at all, the parties shall work together
in good faith to achieve a commercially reasonable resolution thereof.

18.6 Each
policy of insurance which Licensee is required to obtain hereunder shall (a) be with reputable and financially secure insurance carriers
having at least an A rating (A rating or above by A. M. Best) and an A. M. Best Class Size of at least VIII, (b) list each of HFHS, its
trustees, officers, employees, faculty, staff, students, agents and their respective successors, heirs and assigns as additional insured,
(c) be endorsed to provide that the insurer waives all subrogation rights which the insurer otherwise has or could have against any additional
insured, (d) be primary in respect of all additional insured, and (e) provide that the identified insurer will not cancel or fail to
renew the identified insurance without giving HFHS at least 30 days’ prior written notice thereof.

18.7 Within
thirty (30) days following the Effective Date, and thereafter, no later than the day on which any such policy of insurance is renewed
or replaced, Licensee shall provide HFHS with a Certificate of Insurance from each such insurer which evidences compliance by Licensee
with its obligations hereunder. Upon the from-time- to-time request of HFHS, Licensee shall provide HFHS with a copy of the policy, status
of claims and claims history respecting any of the insurance required to be maintained by Licensee hereunder.

18.8 Licensee
will comply with all statutory workers’ compensation and employers’ liability requirements for activities performed under
this Agreement.

19. NOTICES

19.1 Any
notice or payment required to be given to either party under this Agreement will be in writing and will be deemed to have been properly
given and to be effective as of the date specified below if delivered to the respective address given below or to another address as
designated by written notice given to the other party:

the date of delivery if delivered in person;

the date of mailing if mailed by first-class certified mail, postage paid;

the date of mailing if mailed by any global express carrier service that requires the recipient
to sign the documents demonstrating the delivery of such notice or payment.

In the case of
Licensee:	MateraCor, Inc.

30965 La Brise

Laguna Niguel, CA. 92677

Attention: Chief Executive
Officer

In the case of HFHS:	Henry
Ford Health System
Henry
Ford Hospital,
2799 W. Grand Blvd.

Detroit MI. 48202-3450

Attention:

Lisa
Prasad

Vice
President & Chief Innovation Officer

Referring
to: Exclusive License Agreement for stem cell products to treat heart failure, Inventor Hani Sabbah, Ph.D., et al.

Copy

Office
of General Counsel

Henry
Ford Health System

One
Ford Place

Suite

Detroit,

20. ASSIGNABILITY

The
Licensee may assign or transfer this Agreement, including by merger, operation of law, or otherwise, without HFHS’ prior written
consent provided, however, that Licensee and such assignee or transferee agrees to be bound by the terms and conditions of this Agreement
at the time of the assignment or transfer. This Agreement is binding upon and will inure to the benefit of HFHS, its successors and assigns.

21. WAIVER

waiver by either party of any breach or default of any of the agreements contained herein will be deemed a waiver as to any subsequent
and/or similar breach or default. No waiver will be valid or binding upon the parties unless made in writing and signed by a duly authorized
officer of each party.

22. FORCE MAJEURE

22.1 Except
for the Licensee’s obligation to make any payments to HFHS hereunder, the parties shall not be responsible for any failure to perform
due to the occurrence of any events beyond their reasonable control which render their performance impossible or onerous, including,
but not limited to: accidents (environmental, toxic spill, etc.); acts of God; biological or nuclear incidents; casualties; earthquakes;
fires; floods; governmental acts; orders or restrictions; inability to obtain suitable and sufficient labor, transportation, fuel and
materials; local, national or state emergency; power failure and power outages; acts of terrorism; strike; and war.